Bioxytran, Inc. (OTC: BIXT) completed a private placement financing on March 18 2026 that raised approximately $1.2 million in gross proceeds. The transaction issued 21,071,667 shares of common stock at $0.055 per share and granted warrants to purchase up to 19,750,001 additional shares at an exercise price of $0.12, with a five‑year term.
The company will deploy the proceeds primarily for working capital and general corporate purposes, with a focus on advancing its hypoxia and viral‑disease development programs and supporting the launch of its plant‑derived dietary supplement, A‑SUQAR, expected this quarter. The infusion is intended to extend Bioxytran’s runway and provide the financial flexibility needed to pursue its dual‑track strategy of clinical development and near‑term commercialization.
Prior to the financing, Bioxytran reported a net loss of $2.367 million for fiscal 2024, negative EBITDA of $1.602 million, total assets of $139 000, and total debt of $1.094 million. The company’s historical financials show consistent net losses and a small asset base, underscoring the critical need for additional capital to sustain operations and fund research and development.
The issuance of new shares and warrants dilutes existing shareholders, but the company views the dilution as a necessary trade‑off to secure the capital required for continued progress on its clinical milestones and to support the commercialization of A‑SUQAR.
CEO David Platt said the financing “strengthens our balance sheet and supports the advancement of our clinical and development initiatives. In parallel, we are beginning to translate our galectin‑targeting platform into commercial opportunities, including the market introduction of A‑SUQAR®, our plant‑derived dietary supplement expected to launch this quarter. This dual‑track approach allows us to pursue near‑term commercialization while continuing to advance our higher‑value pharmaceutical programs.”
The capital raise provides Bioxytran with a stronger financial foundation, extending its ability to fund research, manage debt, and pursue growth opportunities, while the potential for future warrant exercise adds a layer of dilution that shareholders will need to monitor as the company progresses along its dual‑track roadmap.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.